Samsung Biologics
Samsung Biologics is the world's largest biologics CDMO by capacity, and opened a dedicated ADC conjugation facility in 2025.
Mammalian cell culture at unprecedented scale (Songdo Plant 5), plus ADC conjugation and fill-finish; announced spin-off of Samsung Bioepis (2025).
Pages like this
not linked directly; found by shared links- CompanyLonza
Shares Antibody manufacturing (CHO bioprocessing), Sterile fill-finish and lyophilisation, ADC bioconjugation manufacturing (CDMOs) and the tag supporting.
- CompanyBoehringer Ingelheim BioXcellence
Shares Antibody manufacturing (CHO bioprocessing) and the tag supporting.
- CompanyFUJIFILM Diosynth Biotechnologies
Shares Antibody manufacturing (CHO bioprocessing) and the tag supporting.
- CompanyCatalent (Novo Holdings)
Shares Sterile fill-finish and lyophilisation and the tag supporting.
- CompanyAbzena
Shares ADC bioconjugation manufacturing (CDMOs) and the tag supporting.
- CompanyPiramal Pharma Solutions
Shares ADC bioconjugation manufacturing (CDMOs) and the tag supporting.
- CompanyWuXi XDC
Shares ADC bioconjugation manufacturing (CDMOs) and the tag supporting.
- TechnologyGeneric oncology drug supply and shortage mitigation
Shares Sterile fill-finish and lyophilisation and the tag supporting.